ClinicalTrials.gg
CompletedNCT05414851Updated Jul 16, 2024

Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health

An interventional study of Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet in Heart Disease, Ischemic, Hyperlipidemias and Hypertension, sponsored by University of Rochester. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by University of Rochester · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

This is a randomized trial with a crossover design to investigate the short-term effects of two different dietary patterns on markers of vascular health. A low-carbohydrate diet and a whole-food, plant-based diet will be used. In addition to more traditional markers (cholesterol, blood pressure, inflammation), endothelial progenitor cells and trimethylamine N-oxide will be assessed.

Read the detailed description

This study is an investigation of the short-term effects of two different diets on both conventional as well as newer markers of vascular health among subjects over the age of 50 who have a cardiovascular risk factor. The low-carbohydrate diet will be consistent with low-carbohydrate diet maintenance plans, with "net" carbs kept under 50g per day. The whole-food, plant-based diet will exclude animal foods, oils, and solid fats. Meals will be provided, and subjects will consume each diet for 2 weeks, with a 4-6 week washout period between dietary phases. Subjects will be randomized 1:1 to start with either the plant-based diet or the low-carbohydrate diet. Its primary aim is to assess the short-term effect of a whole-food, plant-based diet and a low-carbohydrate diet on levels of endothelial progenitor cells and trimethylamine N-oxide among this population. Secondarily, we will assess more conventional measures of vascular risk, including cholesterol, weight, blood pressure, insulin resistance, and inflammatory marker, as well as fullness and changes in nutritional intake.

02

Conditions studied

  • Heart Disease, Ischemic
  • Hyperlipidemias
  • Hypertension
03

In context

Myocardial Ischemia

3,242 studies on the registry are indexed under Myocardial Ischemia; 390 are open to participants now.

This study's enrollment of 45 is below the median of 120 across 1,901 interventional studies indexed under Myocardial Ischemia.

Browse Myocardial Ischemia studies →

Lead sponsor

University of Rochester is the lead sponsor of 728 studies on the registry; 115 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >50
  • Diagnosis of any of the following cardiovascular risk factors: hypertension (Diagnosis present in chart or use of antihypertensive medications); hyperlipidemia/dyslipidemia (non-HDL cholesterol ≥ 130 within the past year or current use of antihyperlipidemic medication); prediabetes (HbA1c ≥ 5.7% and \< 6.5% in the past year); diabetes (HbA1c ≥ 6.5% in the past year); obesity (body mass index ≥ 30).
  • Willing and able to comply with the protocol for the duration of the study, including food provision, scheduled meetings and testing visits.
  • Able to speak and read English fluently because counseling and education is only available in English.

Exclusion criteria

Exclusion Criteria:

  • Active malabsorption syndrome (celiac disease, history of gastric bypass within the past year, uncontrolled Crohn's disease, protein-losing enteropathy, etc…)
  • Use of any of the following medications that require close monitoring and adjustment during major dietary change: insulin, sulfonylureas, or warfarin
  • Chronic or acute kidney disease, with eGFR \< 50 on two or more lab tests in the past 6 months
  • Diagnosis of cirrhosis or liver failure
  • Hyperkalemia (defined as potassium >5.4 on two or more lab tests in the past 6 months)
  • Major surgery in the past 3 months
  • Myocardial infarction in the past 6 months
  • Current, active eating disorder as determined by chart review, investigator assessment, or subject history
  • Food allergies or intolerances that would interfere with eating study food or require special accommodation as determined by subject history, investigator assessment, or chart review
  • Consuming a current diet described by the subject as vegetarian, vegan, very low-carbohydrate, or ketogenic
  • Illicit drug use (not including marijuana)
  • High risk alcohol use, based on subject history (defined as greater than 7 drinks/week for women and greater than 14 drinks/week for men)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Whole-Food, Plant-Based Start

    This group starts with the whole-food, plant-based diet, then gets the low-carbohydrate diet after the washout period.

    Other: Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet

  • Experimental
    Low-Carbohydrate Start

    This group starts with the low-carbohydrate diet, then gets the whole-food, plant-based diet after the washout period.

    Other: Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet

Interventions

  • OtherWhole-Food, Plant-Based Diet and Low-Carbohydrate Diet

    Participants will consume two weeks of each diet, with a 4-6 week washout period in between. Meals and snacks are provided for convenience to enhance adherence to each dietary pattern, but subjects can add or include their own home-prepared foods as long as they meet dietary guidelines. Each dietary intervention will include an education session via Zoom teleconference, and at least 2 individual contacts by phone to address questions and assess for adverse events.

06

What researchers measure

Primary outcomes

  1. Endothelial Progenitor Cells

    Time frame: 2 weeks

  2. trimethylamine N-oxide

    Time frame: 2 weeks

  3. HDL function

    Time frame: 2 weeks

Secondary outcomes

  1. Cholesterol Panel

    Total, LDL, HDL, non-HDL cholesterol, and triglycerides

    Time frame: 2 weeks

  2. Blood Pressure

    Time frame: 2 Weeks

  3. Resting Heart Rate

    Time frame: 2 weeks

  4. Weight

    Time frame: 2 weeks

  5. Insulin resistance

    HOMA-IR

    Time frame: 2 weeks

  6. Insulin

    Time frame: 2 weeks

  7. Blood Glucose

    Time frame: 2 weeks

  8. Inflammatory Markers

    hsCRP, TNF-a, IL-6

    Time frame: 2 weeks

  9. Satiety Assessment

    Adapted SLIM (satiety labeled intensity magnitude)

    Time frame: 2 weeks

  10. Food "liking"

    5 food liking factor scales adapted from 5-Factor Satiety Questionnaires

    Time frame: 2 weeks

  11. Change in nutritional intake

    assessed by 3 day food records at baseline and in second week of dietary phase

    Time frame: 2 weeks

07

Study locations

1 site
  • UR Medicine Nutrition in Medicine Research Center
    Webster, New York 14580, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Apr 2024, 16 months.

Of 427 non-industry interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 16 months is below that.

Counting every sponsor, half of 492 studies reached it within 28 months; a quarter within 13 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2022
First posted
Jun 10, 2022
StartActual
Dec 20, 2022
Primary completionActual
Apr 23, 2024
CompletionActual
Apr 23, 2024
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05414851
Responsible party
Thomas M Campbell (Assistant Professor of Family Medicine, University of Rochester) — Principal investigator
First posted
Jun 10, 2022
Start date
Dec 20, 2022
Primary completion
Apr 23, 2024
Completion
Apr 23, 2024
Last update
Jul 16, 2024

Study contacts

Thomas Campbell, MD
principal investigator · University of Rochester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion